Moderna Vaccine Production Shift Down: Due to decreased demand, Moderna is producing fewer COVID-19 vaccines. The goal is to increase the gross margin by 75%–80%. Moderna is discussing ways to accelerate the production of its mRNA-based COVID-19 vaccines with global partners. Partners package the vaccines.
Due to the disease’s prevalence, this reduction plan is a response. Fewer people will want shots as fewer people order them. Moderna expected 50-100 million vaccine doses for the U.S. in the fall. Billions of doses were made annually during the pandemic. With FDA approval, Moderna will distribute the vaccine nationwide. Deals are set to ship to the UK, Canada, and Japan. Talks with the EU are ongoing.
Moderna is developing vaccines for COVID, RSV, and influenza. Discussing with other vaccine makers about these new medicines may take around a year. These deals will likely shape Moderna’s future and ensure its position in the vaccine market for a long time.
Moderna is updating its RSV shot, proving its flu vaccine’s effectiveness for all age groups, including older individuals. In late-stage tests, the flu shot outperformed regular treatments. In an early study, it matched or surpassed Sanofi’s high-dose flu vaccine.
Moderna’s evolving strategy in the post-pandemic era strengthens its position in the vaccine market.
ALSO READ: AI Generated COVID Drug Enters Trials: Potential Effectiveness Against All Variants
